Pharmaceutical companies are pushing back against decisions by cash-strapped European governments to reimburse patients for drugs that haven't been approved to treat their conditions.

National health boards and policy makers say paying for so-called off-label drugs, which are often cheaper than their approved rivals, is necessary to cut national health-care bills. However, pharmaceutical companies argue that encouraging doctors to...

For more details, go to: http://online.wsj.com/articles/drug-companies-oppose-moves-to-reimburse-off-label-medicine-1406287000